Provided by Tiger Trade Technology Pte. Ltd.

FibroBiologics

1.49
+0.05503.85%
Post-market: 1.490.00000.00%19:30 EDT
Volume:105.16K
Turnover:160.51K
Market Cap:9.89M
PE:-0.31
High:1.59
Open:1.53
Low:1.46
Close:1.43
52wk High:12.40
52wk Low:0.6201
Shares:6.66M
Float Shares:6.30M
Volume Ratio:0.80
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7656
EPS(LYR):-8.3501
ROE:-660.08%
ROA:-95.77%
PB:2.13
PE(LYR):-0.18

Loading ...

FibroBiologics Wins US Patent on Fibroblast-Assisted Islet Transplant Engraftment for Type 1 Diabetes

Reuters
·
Aug 11

Fibrobiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

THOMSON REUTERS
·
Aug 11

FibroBiologics Wins European Patent for Sox9 Gene Therapy to Regenerate Cartilage

Reuters
·
Aug 05

Fibrobiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

THOMSON REUTERS
·
Aug 05

FibroBiologics Q2 2026 Earnings: CYWC628 Dosing Begins With $3.5 Million in Cash

TradingKey
·
Aug 05

FibroBiologics is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 04

U.S. Research Roundup-Cloudflare, Replimune, Walmart

Reuters
·
Aug 04

FibroBiologics Faces Material Clinical Trial and Regulatory Risks That Threaten Commercialization Timeline and Long-Term Outlook

TIPRANKS
·
Aug 02

Fibrobiologics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 01

FibroBiologics, Inc. - Common Stock Q2 EPS $(0.66) Beats $(0.72) Estimate

Benzinga Earnings
·
Aug 01

Press Release: FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

Dow Jones
·
Aug 01

Fibrobiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

THOMSON REUTERS
·
Aug 01

Fibrobiologics - Interim Results for Cywc628 Trial Expected in Second Half of 2026

THOMSON REUTERS
·
Aug 01

Fibrobiologics Q2 FY26 Net Loss Narrows to $4.12 Million from Year-ago Quarter

Reuters
·
Aug 01

FibroBiologics Announces Special Stockholder Meeting

Reuters
·
Jul 31

Fibrobiologics Inc Expected to Post a Loss of 72 Cents a Share - Earnings Preview

Reuters
·
Jul 27

FibroBiologics Faces Nasdaq Delisting, Appeals Planned

TIPRANKS
·
Jul 25

Fibrobiologics Faces NASDAQ Delisting After Bid Price Stays Below $1

Reuters
·
Jul 25

Fibrobiologics Director Kathleen Hallisey Rubins Files Initial Beneficial Ownership Statement

Reuters
·
Jul 17

Fibrobiologics - Registers Resale of up to 12.53 Mln Shares of Common Stock by Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Jul 10